Lilly and Evotec Announce $1 Billion Collaboration to Develop Novel Targeted Therapies for Metabolic Diseases, Focusing on Kidney Disease and Diabetes

News on January 19, 2022 /BioValleyBIOON/ --Eli Lilly(Eli Lilly) and Evotec SE recently announced jointly that they haveMetabolic DiseasesA drug discovery collaboration has been reached in the field, with a focus on kidney disease andDiabetes。

This collaboration will leverage Evotec's extensive experience and expertise in the field of metabolic diseases, as well as its unique and extensive database of patients with kidney disease, integrated data-driven drug discovery and development platform, to identify and validate promising new targets for therapeutic intervention.

The collaboration initially lasts for three years. In addition to an undisclosed upfront payment, Evotec is also eligible to receive success-based discovery, development, regulatory, and commercial milestone payments of up to $180 million per program, as well as tiered royalties on net sales of any products arising from the collaboration, with a potential total value of up to $1 billion.

Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, stated: "We are very pleased to establish this research partnership with Eli Lilly and Company. Over the past few years, Evotec has systematically built a proprietary patient database by conducting multi-omics analyses on biological samples from biobanks covering metabolic and renal diseases. The combination of Evotec’s patient-derived molecular data with an omics-supported multimodal drug discovery platform will provide our partners with the highest quality drug candidates. We are honored to collaborate with...Eli LillyInDiabetes"And collaborate in the field of kidney diseases, the company is a leading player in these areas." (Bioon.com)

Source of Original Text:Evotec and Lilly Enter into Drug Discovery Collaboration in Metabolic Diseases